Geneva University Hospitals
Geneva, Canton of Geneva, 1211, Switzerland
Location status: Recruiting
NCT Number: NCT06855784
This study is aimed at women currently going through menopause, either as part of the natural process (physiological menopause), or following hormonal treatment for breast cancer. There are several ways of slowing the weight gain frequently encountered in this situation, reducing the intensity of menopause-related symptoms and improving quality of life in this context.
In this trial, the investigators examine the efficacy and possible adverse effects of intermittent fasting compared with a control intervention. Participation lasts 14 weeks, with an optional 12-month follow-up. Study participants are randomly assigned to either the intervention group or the control group. In the intervention group, study participants fast for 16 hours per day and eat over a period of 8 hours (intermittent fasting often called time-restricted eating [TRE] 16h/8h). In the control group, the usual eating pattern is continued for 12 weeks.
The main objective of the study is to evaluate the efficacy of TRE in terms of weight and fat loss, improvement in metabolic profile, menopausal symptoms and bone health. In addition, the study team closely monitors any adverse effects.
Interested in participating?
Request Info45 year–60 year
Female
Interventional
Not applicable
Geneva, Canton of Geneva, 1211, Switzerland
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be advised to eat only during a self-selected window of 8 hours over the 24-hour cycle, with a 1-hour allowance according to their daily routine.
Other names: TRE 16h/8h
Participants will be advised to eat 2 to 3 meals every day according to their eating habits and social activities
Time frame: From randomization visit to close-out visit (12 weeks)
Measured (in Kg) in light clothing using a calibrated medical-grade scale
Time frame: From randomization visit to close-out visit (12 weeks)
Measured (in Kg) by dual-energy x-ray absorptiometry (DXA)
Time frame: From randomization visit to close-out visit (12 weeks)
Assessed by questionnaire
Time frame: From randomization visit to close-out visit (12 weeks)
Measured (in g/cm3) by dual-energy x-ray absorptiometry (DXA)
Time frame: From randomization visit to close-out visit (12 weeks)
C-telopeptide cross-linked type 1 collagen (CTX) measured (in ng/L) by clinical chemistry
Time frame: From randomization visit to close-out visit (12 weeks)
Procollagen type 1 N-terminal propeptide (P1NP) measured (in μg/L) by clinical chemistry
Time frame: From randomization visit to close-out visit (12 weeks)
Joint pain assessed by questionnaire (0 = absent to 7 = Extremely bothered)
Time frame: From randomization visit to close-out visit (12 weeks)
Expressed in percent of baseline value (body mass index = weight in Kg divided by the height in meters squared, unit Kg/m2)
Time frame: From randomization visit to close-out visit (12 weeks)
Measured (in cm) with a measuring tape, following the WHO 2008 Expert Report
Time frame: From randomization visit to close-out visit (12 weeks)
Measured (in cm) with a measuring tape, following the WHO 2008 Expert Report
Time frame: From randomization visit to close-out visit (12 weeks)
Measured (in mmHg) with an arm cuff in the sitting position
Time frame: From randomization visit to close-out visit (12 weeks)
Measured (in mmol/L) by clinical chemistry
Time frame: From randomization visit to close-out visit (12 weeks)
Total cholesterol, LDL cholesterol, triglycerides and HDL cholesterol concentrations measured (in mmol/L) by clinical chemistry
Time frame: From randomization visit to close-out visit (12 weeks)
Measured (in Kg) by dual-energy x-ray absorptiometry (DXA)
Time frame: From randomization visit to close-out visit (12 weeks)
Fat mass and fat-free mass (in Kg) measured by bioelectrical impedance analysis (BIA)
Time frame: From randomization visit to close-out visit (12 weeks)
Measured (in Kg) by handgrip strength
Time frame: From randomization visit to close-out visit (12 weeks)
Measured by continuous glucose monitoring
Time frame: From randomization visit to close-out visit (12 weeks)
Measured by high-throughput mass spectrometry metabolomics
Time frame: From randomization visit to close-out visit (12 weeks)
Measured by actigraphy (in activity counts, CamNTech proprietary algorithm) and by the International Physical Activity Questionnaire (IPAQ, aggregated in MET-minutes/week)
Time frame: From randomization visit to close-out visit (12 weeks)
Measured by actigraphy assessed as time of sleep onset and wake-up in 24-hour cycle
Time frame: From randomization visit to close-out visit (12 weeks)
Measured by actigraphy
Time frame: From randomization visit to close-out visit (12 weeks)
Measured by body temperature wearable device
Time frame: From randomization visit to close-out visit (12 weeks)
Assessed by the Pittsburgh Sleep Quality Index [PSQI, minimum score = 0 (better); maximum score = 21 (worse)]
Time frame: From randomization visit to close-out visit (12 weeks)
Duration from the first to last caloric intake over 24-hour cycle
Interested in participating?
Request InfoUniversity Hospital, Geneva
Other
Time-Restricted Eating to Improve Body Composition and Symptoms in Menopause and HOrmone-sensitive Breast Cancers (TREMHO) - An Open-label Randomized Controlled Trial
Acronym: TREMHO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07822230
Body Weight, Climactericum
Porto Alegre, Rio Grande do Sul, Brazil
View Trial DetailsNCT07472881
Body Weight, Menopause
Keelung, Taiwan
View Trial DetailsNCT06497946
Behavior, Behavior, Animal
Porto Alegre, Rio Grande do Sul, Brazil
View Trial DetailsNCT07705724
Body Weight, Menopause
Little Rock, Arkansas, United States
View Trial Details